Non-cognitive behavior associated with development of Alzheimer pathology in APPswePS1dE9 mice and an effect of long-term paroxetine treatment

TY - CONF

T1 - Non-cognitive behavior associated with development of Alzheimer pathology in APPswePS1dE9 mice and an effect of long-term paroxetine treatment

AU - Bouzinova, Elena

AU - Olesen, Louise Ørum

AU - Wiborg, Ove

PY - 2015/11/5

Y1 - 2015/11/5

N2 - Alzheimer’s disease (AD) is a devastating illness characterized by a progressive loss of cognitive, social, and emotional functions, usually starting with memory impairments followed by more global cognitive deficits and neuropsychiatric symptoms. We have used APPswePS1dE9 mice model of AD to characterize non-cognitive behavioral changes associated with development of pathology and differentiated from normal aging. We have used open field and elevated plus maze tests to capture the behavioral pattern of Tg and Wt mice and performed these tests at 9, 12, 15, and 18 months of age. The principal component analysis was used to generalize conclusions based on all behavioral parameters registered during the tests. The long term treatment with the selective serotonin reuptake inhibitor paroxetine (prx) was used to depict the role of 5-HT in the aforementioned behaviour. Alterations in the non-cognitive behavioural phenotype become apparent beyond 15 months of age. We observed decline in locomotion, in exploration and risk assessment behaviour specific for the AD pathology, which were delayed by treatment with prx. Furthermore, the analysis of locomotion at 18 months of age is sufficient to describe the AD associated non-cognitive phenotype.

AB - Alzheimer’s disease (AD) is a devastating illness characterized by a progressive loss of cognitive, social, and emotional functions, usually starting with memory impairments followed by more global cognitive deficits and neuropsychiatric symptoms. We have used APPswePS1dE9 mice model of AD to characterize non-cognitive behavioral changes associated with development of pathology and differentiated from normal aging. We have used open field and elevated plus maze tests to capture the behavioral pattern of Tg and Wt mice and performed these tests at 9, 12, 15, and 18 months of age. The principal component analysis was used to generalize conclusions based on all behavioral parameters registered during the tests. The long term treatment with the selective serotonin reuptake inhibitor paroxetine (prx) was used to depict the role of 5-HT in the aforementioned behaviour. Alterations in the non-cognitive behavioural phenotype become apparent beyond 15 months of age. We observed decline in locomotion, in exploration and risk assessment behaviour specific for the AD pathology, which were delayed by treatment with prx. Furthermore, the analysis of locomotion at 18 months of age is sufficient to describe the AD associated non-cognitive phenotype.

KW - Alzheimer Disease

KW - mouse model

KW - Behavior

M3 - Poster

T2 - Psykiatriens 10. Forskningsdag

Y2 - 5 November 2015 through 5 November 2015

ER -